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Simian virus 40 (SV40) contains an essential protein, large tumor antigen (Tag), which assists in viral replication and causes cell
transformation and immortalization. Our laboratory has examined plasmid DNA, expressing SV40 Tag under two different promoters, for use
in potential cancer vaccination strategies. One plasmid, pSV3-neo, failed to induce SV40 Tag antibody, produced a weak cell-mediated
response, and only partial protection in murine experimental tumor challenge systems. The second plasmid, pCMV-Tag, induced antibodies
to SV40 Tag, produced a robust cell-mediated response, and invoked complete tumor immunity in vivo. The induction of CD4+ and CD8+ T
cell responses following plasmid DNA immunization and tumor cell challenge reflected a type 1 cytokine secretion profile. Our hypothesis
for this differential immune response is that pCMV-Tag exhibits a higher level of transgene expression due to a more efficient promoter. We
determined that pCMV-Tag levels of SV40 Tag mRNA and protein expression were higher when compared to pSV3-neo. A threshold
amount of SV40 Tag may be required to stimulate antibody production and provide complete systemic tumor immunity.
D 2004 Elsevier Inc. All rights reserved.
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Simian virus 40 (SV40) is a polyoma virus of rhesus
monkey origin. This DNAvirus was initially discovered as a
contaminant of poliovirus vaccines in 1960 and represents
one of the best studied viruses in modern history (reviewed
in Butel and Lednicky, 1999). SV40 has been used to
discern the mechanisms of molecular processes in eukary-
otic cells and as a molecular tool to study cellular
transformation events. Within its genome, SV40 encodes
two early nonstructural proteins that share the 82 amino
terminal amino acids referred to as large and small tumor
antigen. The large tumor antigen (Tag) is composed of 7080042-6822/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2004.08.041
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E-mail address: ronald.kennedy@ttuhsc.edu (R.C. Kennedy).amino acids and provides multiple functions including an
essential role in viral replication and a transforming capacity
and oncogenic potential both in vitro and in vivo. Although
SV40 Tag is mainly localized within the nucleus of the cell,
a small amount is expressed on the cell surface of
transformed cells. SV40 Tag represents a viral-encoded
tumor-specific antigen and a target for antitumor immune
responses and tumor immunity (reviewed in Benton and
Kennedy, 1998). In certain instances, murine cells trans-
formed with SV40 in vitro can induce tumors in vivo when
inoculated into syngeneic murine hosts. This represents an
excellent model system to evaluate a variety of cancer
vaccination strategies in vivo that target SV40 Tag.
Immunization with plasmid DNA is a simple, adaptable,
and practical approach to immunotherapy when compared to
more traditional vaccination strategies (Quinn et al., 2002).
Plasmid DNA constructed with a gene encoding an antigen of005) 28–37
Fig. 1. In vitro expression of SV40 Tag mRNA following transfection with
plasmid DNA. RT-PCR results 48 h after transient transfection of NIH/3T3.
(1) Standard size marker, (2) mock transformant, (3) pSV2-neo, (4) pSV3-
neo, (5) pcDNA 3.1, and (6) pCMV-Tag.
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immune responses that invoke protective immunity. Indeed,
DNA vaccines have been shown to elicit both humoral and
cell-mediated immune responses that can result in protective
immunity in a variety of systems (Sin and Weiner, 2000;
reviewed in Barouch et al., 2002; Reyes-Sandoval and Ertl,
2001). Our laboratory has employed plasmid DNA contain-
ing the SV40 Tag gene under the control of the SV40
promoter, designated pSV3-neo, and demonstrated that
prophylactic tumor immunity could be induced in mice
against a nonmetastasis solid tumor challenge. Tumor
immunity was associated with the induction of major
histocompatibility complex (MHC) class I cytotoxic T
lymphocytes (CTL) as little to no antibody responses were
generated following immunization of mice with this plasmid
DNA (Bright et al., 1996). When the induction of tumor
immunity by pSV3-neo immunization was examined in a
more stringent in vivo tumor model system, namely, an
experimental murine pulmonary metastasis model, partial to
no systemic tumor immunity was observed (Watts et al.,
1999). This was in contrast to a recombinant SV40 Tag
(rSV40 Tag) protein immunization, where complete systemic
tumor immunity was observed (Shearer et al., 1993). Tumor
immunity resulting from Tag protein immunization was
associated with the induction of antibodies to SV40 Tag and
the induction of CD4+ T cell responses (Bright et al., 1994;
Kennedy et al., 2003; Watts et al., 1999).
To improve upon our plasmid DNA immunization
strategy, we constructed a second plasmid that contained
the SV40 Tag gene under the control of the cytomegalovirus
(CMV) promoter, designated pCMV-Tag. We hypothesized
that the stronger CMV promoter would produce more SV40
Tag than the pSV3-neo plasmid DNA and induce antibody,
cell-mediated responses, and systemic tumor immunity
following immunization of mice. To address our hypothesis,
we compared the in vitro levels of mRNA and protein
expression generated by the two plasmids following transient
transfection experiments in a mouse fibroblast cell line.
Additionally, we compared the ability of the two plasmid
DNA preparations to induce antibody, cell-mediated
responses, and tumor immunity in two different murine
experimental tumor models.
The results described herein demonstrate that pCMV-Tag
induced higher levels of mRNA and based on Western blot
analysis more SV40 Tag when compared to pSV3-neo.
Immunization of mice with pCMV-Tag also generated
antibody responses to SV40 Tag a robust cell-mediated
response and induced complete tumor immunity following
experimental tumor cell challenge in both animal models,
unlike pSV3-neo immunization. These data suggest that the
differential ability to induce antibody, cell-mediated
responses, and systemic tumor immunity in mice by the
two plasmids may arise from differences in plasmid
promoter strength. A threshold level of antigen may be
necessary to invoke components of the immune response
involved in antibody production.Results
Examination of in vitro mRNA and protein expression by
plasmid DNA
The expression of mRNA encoding for SV40 Tag was
evaluated to determine if the plasmids were able to
transcribe the gene of interest. The presence of SV40 Tag
mRNA was determined by RT-PCR in NIH/3T3 cells
transfected with various plasmid DNA preparations. A
molecular standard marker was utilized with a weight
standard of 300 and 200 bp (Fig. 1, lane 1). Both the
pSV3-neo and pCMV-Tag plasmid-transfected NIH/3T3
cells expressed SV40 Tag mRNA (Fig. 1, lanes 4 and 6,
respectively). The expected 300 bp RT-PCR product was
observed. pSV2-neo and pcDNA 3.1 were utilized as
control plasmids because the Tag gene is not expressed in
either plasmid, and no SV40 Tag mRNAwas detected (Fig.
1, lanes 3 and 5, respectively). pCMV-Tag-transfected cells
expressed approximately 1.3 times more SV40 Tag mRNA
compared to pSV3-neo-transfected cells when band inten-
sities were analyzed by a computer algorithm (data not
shown). These data indicate that pCMV-Tag expressed more
amplified SV40 Tag mRNA than pSV3-neo when used to
transfect NIH/3T3 cells.
Western blot analysis was performed to confirm SV40
Tag protein expression in vitro. Whole cell lysates from the
transient transfection assays were evaluated for the presence
of SV40 Tag. A band of approximately 90 kDa was
observed for the mKSA tumor cell lysate (Fig. 2, lane 2),
pSV3-neo-transfected NIH/3T3 cell lysate (Fig. 2, lane 5),
and pCMV-Tag-transfected NIH/3T3 cell lysate (Fig. 2, lane
7), indicating that SV40 Tag protein was expressed. A
positive control of the rSV40 Tag preparation is also shown
(Fig. 2, lane 1). No detectable levels of SV40 Tag protein
expression were found by Western blot analysis in the NIH/
3T3 cell lysate (Fig. 2, lane 3), pSV2-neo-transfected NIH/
3T3 cell lysate (Fig. 2, lane 4), and pcDNA 3.1-transfected
NIH/3T3 cell lysate (Fig. 2, lane 6). Based on band
intensities, the pCMV-Tag-transfected cell lysate contained
approximately 1.7 times more SV40 Tag than the pSV3-neo
cell lysate (data not shown). These data confirm the
presence of SV40 Tag in NIH/3T3 cells transfected with
either pSV3-neo or pCMV-Tag and suggest that pCMV-Tag-
transfected cells express higher levels of SV40 Tag in vitro
than pSV3-neo-transfected cells.
Table 1
Humoral immune response to SV40 Tag following rSV40 Tag and DNA
immunization
Immunization Antibody titers 14 days
post third immunization,
mean (range)
Antibody titers 14 days
post fourth immunization,
mean (range)
pcDNA3.1 b50 b50
rSV40 Tag 1000 (50–3200) 1800 (200–6400)
pSV3-neo b50 b50 (b50–50)
pCMV-Tag 5120 (3200–6400) 10,880 (6400–25,600)
Fig. 2. In vitro SV40 Tag expression following transfection with plasmid
DNA. Western blot analysis 48 h after transfection. (1) rSV40-Tag, (2)
mKSA lysate, (3) NIH/3T3 cell lysate, (4) pSV2-neo-transfected cell lysate,
(5) pSV3-neo-transfected cell lysate, (6) pcDNA 3.1-transfected cell lysate,
and (7) pCMV-Tag-transfected cell lysate.
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plasmid DNA immunization
In order to examine humoral immune responses to
SV40 Tag, sera collected from rSV40 Tag and DNA-
immunized mice 14 days following third and fourth
injections were measured by ELISA (Table 1). The anti-
SV40 Tag mean reciprocal end point titers after the third
immunization of plasmid DNA were less than 50 for
pSV3-neo and 5120 for pCMV-Tag-immunized mice.
Mean reciprocal end point titer values after the fourth
immunization of plasmid DNA were less than 50 for
pSV3-neo and 10880 for pCMV-Tag-immunized mice.
Two of the nine pSV3-neo-immunized mouse sera
exhibited a weak antibody response to SV40 Tag and
had endpoint titers of 50. Sera from control plasmid DNA
(pcDNA 3.1)-immunized mice exhibited end point titer
values for post third and fourth immunizations that were
less than 50. These data compare with mean anti-SV40
Tag endpoint titers value for rSV40-Tag-immunized mice
of 1000 and 1800 for post third and fourth immuniza-
tions, respectively. Preimmune serum from all immunized
mice groups failed to recognize SV40 Tag (data not
shown). To further evaluate antibody responses in immu-
nized mice, representative SV40 Tag binding curves are
shown in Fig. 3. The slopes of the SV40 Tag binding
curves are similar with respect to serum obtained from
rSV40 Tag and pCMV-Tag-immunized mice. The pSV3-
neo-immunized mice exhibited negligible antibody
responses to SV40 Tag at any of the serum dilutions that
were examined. These data indicate that pCMV-Tag mice
induce stronger antibody responses to SV40 Tag when
compared to either rSV40 Tag or pSV3-neo-immunized
mice.
Examination of the cell-mediated immune response induced
by plasmid DNA immunization
To examine cellular immune responses to SV40 Tag,
spleenocytes collected from rSV40 Tag and DNA-immu-
nized mice following four injections and 7 days post-
challenge with mKSA were stimulated in vitro, stained for
CD4 or CD8, along with intracellular straining for IL-2, IL-
4, IL-10, IFN-g, and the relative frequencies of each
measured by flow cytometry. In each case, the mKSA-
challenged mice exhibited higher, on average 40%, total
CD4 and CD8 levels compared to the unchallenged mice(Table 2). No significant difference in total CD4 and CD8
levels was observed between the vaccinated groups. When
comparing the total type 2 cytokine secreting cells IL-4 and
IL-10, all frequencies fell below 1% of the total lympho-
cyte population. In contrast, the type 1 cytokine-producing
cells, IL-2 and IFN-g, comprised a significant portion of
the control lymphocyte population comprising approxi-
mately 5% each of the total. All mKSA-challenged groups
exhibited an increase in type 1 cytokine-producing cells
with the exception of the pcDNA3.1 group that decreased
slightly. The pCMV-Tag group exhibited the highest levels
of IL-2-producing cells at 10.08% of the total population, a
greater than 50% increase compared to control unchal-
lenged mice. The frequency of IFN-g-producing cells was
highest in the unvaccinated mKSA-challenged group with
14.15% of the total population a 60% increase compared to
unchallenged control. Also, the pSV3-neo and pCMV-Tag-
immunized challenged groups exhibited a greater than 50%
increase in IFN-g-producing cells with 11.55% and
10.81%, respectively.
We next compared the relative frequencies of the
cytokine-producing cells in the CD4+ lymphocyte popula-
tions. Again there was no significant amount of the Th1
cytokine-producing cells IL-4 and IL-10 from any of the
groups (b1%). CD4+/IL-2 levels decreased in all of the
mKSA-challenged groups with the exception of the pCMV-
Tag group where they increased slightly. The pcDNA3.1
group exhibited a significant decrease in the frequency of
CD4+/IL-2 cells dropping from 19.30 in the control
unchallenged mice to 10.23%. Comparing the CD4+/IFN-
g levels, all challenged groups exhibited an increase with
the exception of the pcDNA3.1-vaccinated group, which
fell to 7% compared with 12.42% for the unchallenged
group. Within the challenge groups, the unvaccinated
challenged group exhibited the greatest number of CD4+/
IFN-g cells at 30.41% compared to 18.07% and 19.15% for
the pSV3-neo and pCMV-Tag groups, respectively.
We next compared the relative frequencies of the
cytokine-producing cells in the CD8+ lymphocyte popula-
tion. Again the type 2 cytokine-producing cells IL-4 and
IL-10 since the frequency of total is less than 1%. CD8+/
IL-2 levels remained constant between the challenged
groups compared to the unchallenged control with the
exception of the pCMV-Tag-vaccinated group, which
increased to 17.11%. This is an increase of over 50%
Fig. 3. Representative binding curves of mouse sera to SV40 Tag following rSV40 Tag and DNA immunization. Serum obtained from mice immunized with
pCMV-Tag (E–E), rSV40-Tag (!–!), and pSV3-neo (n–n). Themean of triplicate values is depicted. The range of values did not exceed 1%of themean value.
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frequency of CD8+/IFN-g-producing lymphocytes actually
decreased in the unvaccinated mKSA-challenged group by
over 60% compared to the vaccinated and challenged
groups. While there were slight increases in the levels of
CD8+/IFN-g-producing lymphocytes in the pSV3-neo and
pCMV-Tag groups.Table 2
Relative frequencies of CD4+ and CD8+ cytokine-producing cells
following vaccination and mKSA challenge
Cx
mKSA
Tag
mKSA
pcDNA3.1
mKSA
pSV3neo
mKSA
pCMV-SV40
Tag mKSA
Total
CD4 36.50 33.99 41.29 41.51 38.40
CD8 5.35 4.36 3.92 5.34 5.21
IL-2 7.75 6.07 4.72 7.77 10.08
IL-4 0.20 0.27 0.22 0.35 0.24
IL-10 0.55 0.28 0.27 0.51 0.44
IFN-g 14.15 8.17 4.84 11.55 10.81
CD4+
IL-2 18.60 15.66 10.23 16.63 23.18
IL-4 0.27 0.38 0.09 0.31 0.37
IL-10 0.60 0.50 0.21 0.47 0.61
IFN-g 30.41 14.38 7.00 18.07 18.15
CD8+
IL-2 7.43 9.66 8.08 9.38 17.11
IL-4 0.17 0.83 0.55 1.34 1.52
IL-10 0.52 0.91 0.75 4.95 1.6
IFN-g 11.44 37.05 29.72 43.31 41.60
Groups of three mice were immunized and challenged as described. Seven
days postchallenge, the mice were euthanized, spleenocytes processed, and
stained for various cell surfacemarkers and intracellular cytokine production.
The values represent the average relative frequency per group of three based
on ex vivo analysis of 1  105 events and triplicate determinations per
individual. Staining with unrelated control isotype antibody has been
subtracted as background staining.Evaluation of tumor immunity
Previous studies in our laboratory have shown that
BALB/c mice immunized with rSV40 Tag are completely
protected in an intraperitoneal nonmetastasis solid tumor
challenge (Shearer et al., 1993). Similarly, pSV3-neo mice
also exhibited tumor immunity to a low dose solid tumor
challenge (2 LD50) (Bright et al., 1996). To evaluate tumor
immunity in this challenge system, mice immunized with
plasmid DNA and SV40 Tag were challenged with a high
dose of tumorigenic cells (100 LD50), and tumor immunity
was determined by mean survival time. Mice immunized
with pCMV-Tag and rSV40 Tag showed complete protec-
tion against intraperitoneal tumor challenge and survived
greater than 60 days. Mice immunized with the control
plasmid DNA exhibited no immunity as all succumbed to
the tumor challenge by 21 days. Partial protection was
observed in the pSV3-neo-immunized group as four of nine
mice succumbed to the lethal effects of the tumor challenge
by 30 days while the remaining five mice survived beyond
60 days posttumor challenge (Table 3).
Tumor protection was further evaluated in a more
stringent model of tumor immunity, namely, an experimen-
tal pulmonary metastasis model where the tumorigenic cell
challenge is by intravenous inoculation. Tumor immunity is
evaluated by either survival after tumor challenge or the
presence of tumor cell foci in the lungs of challenged mice.
rSV40 Tag and pCMV-Tag-immunized mice showed
complete protection, and immunized mice survived greater
than 90 days postchallenge. Furthermore, both immuniza-
tions with pCMV-Tag and rSV40 Tag prevented tumor
establishment, as no tumor foci were detected in lungs
obtained from mice 18 days after tumor cell challenge
(Table 4). All mice immunized with pcDNA 3.1 and pSV3-
Table 3
Tumor immunity following rSV40 Tag and DNA immunization in an
intraperitoneal solid tumor challenge model
Immunization Percentage of survival
(No. survived/No. challenged)
pcDNA3.1 0 (0/10)
rSV40 Tag 100 (10/10)
pSV3-neo 56 (5/9)
pCMV-Tag 100 (10/10)
Fig. 4. Representative tumor foci in the lungs of mice following
immunization and intravenous tumor cell challenge. (A) pSV3-neo; (B)
pcDNA 3.1; (C) pCMV-Tag immunization.
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examining lung tumor foci, pSV3-neo-immunized mice
contained between 12 and 32 tumor foci and pcDNA 3.1
mice exhibited a range of 32–60 tumor foci (Table 4).
Representative lung tumor foci from immunized mice are
shown in Fig. 4. These data indicate that pCMV-Tag was
superior in generating tumor immunity when compared to
pSV3-neo in these two tumor challenge model systems.Discussion
Despite many advantages DNA vaccines possess over
traditional vaccination strategies such as adaptability and
ease of production, a major shortcoming is delivery of
antigen for immune response (Michel et al., 2002). Multiple
injections at high dosages are usually required to induce a
protective immune response. In this study, we evaluated
antibody responses to SV40 Tag and the ability to protect
from a tumorigenic cell line experimental challenge in mice
immunized with a plasmid comprised of the SV40 Tag gene
driven by either the CMV or SV40 promoter.
Previous work in our laboratory has examined the
immunological mechanisms and effects of a variety of
SV40 Tag vaccination strategies to provide in vivo tumor
immunity in mice experimentally challenged with a tumori-
genic SV40-transformed cell line. Two different murine
challenge models have been employed in order to evaluate
SV40-Tag-induced tumor immunity. In a nonmetastasis solid
tumor model, BALB/c mice were immunized with either
protein (rSV40 Tag) or plasmid DNA (pSV3-neo) and
challenged intraperitoneally with a low dose (2 LD50) of
the tumorigenic mKSA cell line (Bright et al., 1996). rSV40-
Tag-immunized mice elicited only an SV40 Tag antibody
response to the mKSA cell challenge while pSV3-neo-Table 4
Tumor immunity following rSV40 Tag and DNA immunization in an
experimental pulmonary metastasis tumor challenge model
Immunization Tumor lung cell focia Percentage of survivalb
pcDNA3.1 32–60 0
rSV40 Tag 0 100
pSV3-neo 12–32 0
pCMV-Tag 0 100
a Represents the range of lung tumor cell foci obtained from three
individual mice that were examined 18 days posttumor cell challenge.
b Percentage of survival of seven individual mice.immunized mice generated a CD8+ MHC class I restricted
CTL response. Yet even with these differences in immune
response, tumor immunity was observed in all protein and
plasmid DNA-immunized mice. In our more stringent
pulmonary metastasis model (Watts et al., 1997), BALB/c
mice were immunized with either protein (rSV40 Tag) or
plasmid DNA (pSV3-neo) and challenged intravenously with
a lethal dose of the mKSA cell line (Watts et al., 1999). Once
more, rSV40 Tag elicited only an antibody response to SV40
Tag while no humoral response was observed in pSV3-neo-
immunized mice. rSV40-Tag-immunized mice were com-
pletely protected while pSV3-neo-immunized mice were
either partially protected or not protected at all.
In this current study, it has been shown that tumor
immunity differed considerably between mice immunized
with plasmid DNA preparations and recombinant protein. As
was the case with rSV40 Tag mice, pCMV-Tag-immunized
mice were completely protected from a lethal challenge of the
mKSA cell line in both the intravenous and intraperitoneal
tumor challenge models while pSV3-neo-immunized mice
only exhibited partial protection. pCMV-Tag-immunized
mice produced a detectable humoral immune response while
little to no detectable levels of antibodies to SV40 Tag were
observed in pSV3-neo-immunizedmice. Additionally, higher
in vitro protein and mRNA expression of SV40 Tag was
detected in transfection experiments using pCMV-Tag
compared to pSV3-neo. The nature of plasmid DNA used
for immunization, such as the promoter driving transgene
expression, could correlate to differences in immune
responses observed in immunized mice.
Plasmid DNA employed for immunization in BALB/c
mice differed in that pSV3-neo plasmid DNA contains the
SV40 Tag gene under regulatory control of the SV40
promoter, while the SV40 Tag gene is under the control of
the CMV promoter in the pCMV-Tag plasmid. It has recently
been shown by other investigators that transcriptional
regulatory elements in plasmid constructs directly relate to
the expression of a desired gene (Xu et al., 2001). Studies
employing cells from human cervical carcinoma (HeLa),
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cells from the umbilical cord vein (ECV304) were transfected
in vitro with various constructs of plasmid DNA expressing
the firefly luciferase gene as a reporter transgene. Results
obtained for both in vitro and in vivo transfection studies
showed consistently higher transgene expression in plasmids
containing the CMVpromoter rather than the SV40 promoter.
Similar results have been obtained in comparison studies with
NIH/3T3 cells transfected with plasmids containing either the
CMV or SV40 promoters controlling the expression of the
bacterial Cm acetyltransferase (cat) reporter transgene
(Foecking and Hofstetter, 1986). Again, cat transiently
transfected NIH/3T3 cells showed higher transgene expres-
sion using plasmid DNA containing the CMV promoter
rather than plasmids maintaining the SV40 promoter.
Differences in immune responses between pCMV-Tag
and pSV3-neo-immunized mice are associated with the
induction of antibody responses following SV40 Tag
expression in vivo. Therefore, the level of antigen expres-
sion in a plasmid after uptake into muscle cells may play a
role in determining the resulting immune response. Indeed,
the induction of virus-specific CD8+ CTL increased with
increasing levels of antigen until a threshold has been
reached (Wherry et al., 1999). It has also been shown
previously that a threshold level of human immunodefi-
ciency virus-1 gag and env expression induced by plasmid
DNA containing the CMV promoter elicited a higher level
of immune responses, while large doses of a plasmid
expressing these transgenes under a weak promoter failed to
generate a comparable antibody response (Galvin et al.,
2000). It is reasonable to speculate that pCMV-Tag
expresses a larger amount of SV40 Tag within the muscle
cell cytoplasm at the site of injection. A high rate of pCMV-
Tag expression of SV40 Tag may deplete vital structural and
metabolic resources in an infected cell containing the
plasmid. This could result in a necrotic cell ready for
ingestion by an antigen presenting cell (APC). SV40 Tag
presentation by MHC class II expression in the APC follows
and activation of CD4+ cells occurs that induces antibody
responses to SV40 Tag. An additional explanation for
immunological differences observed between plasmid
DNA-immunized mice is the amount of antigen that reaches
a corresponding lymph node (Boyle et al., 1996). Due to
strong expression by pCMV-Tag, SV40 Tag may be released
into circulation from necrotic cells or occasionally by cell
surface expression and escape. If enough antigen accesses a
lymph node, SV40 Tag is taken up by an APC (i.e.,
dendritic cell), and through MHC class I and II presentation
activates T cells (Ochsenbein et al., 1999). CD4+ T cells
subsequently release cytokines to stimulate B cells, and
antibodies to SV40 Tag are generated. Additionally, CD8+
T cells can be activated and promote effector functions
associated with CTL responses. Thus, in this system CD4+
T helper cells are considered a necessary factor in attaining
complete tumor rejection (Kennedy et al., 2003). The lower
level of expression of the transgene in pSV3-neo mice couldresult in the failure of the antigen to reach lymph nodes and
activate APCs. This in turn could result in failed CD4+
response, evoking partial tumor protection resulting from
only CD8+ T cell activation as has been reported in other
systems (Ochsenbein et al., 2001). Our results do not appear
to support such a scenario. Flow cytometric analysis clearly
demonstrates that both of the SV40-Tag-expressing plas-
mids induced CD4+ Th1 type cells that can secrete both IL-
2 and INF-g. This is similar to what was observed with the
rSV40 Tag immunization and may reflect a skewing of the
immune response as a result of the tumor cell challenge. The
CD4+ Th1 response induced by pSV3-neo and pCMV-Tag
was increased when compared to a control plasmid
immunization. It also appears that the CD8+ T cells secreted
type 1 cytokines that are indicative of Tc1 that can function
as CTL and mediated tumor immunity. Little difference
were observed in the CD4+ and CD8+ T cell responses
based on flow cytometry between the two DNA plasmid
immunization schemes. This similarity was not reflected in
the differences observed with regards to antibody responses
and in vivo tumor immunity where the pCMV-Tag plasmid
generated superior responses. It is interesting to note that
pCMV-Tag immunization did generate the highest levels of
CD4+ and CD8+ T cells capable of secreting IL-2. Thus, the
mechanism(s) of this differential tumor immunity remains
unclear but could include a role for IL-2-secreting T cells.
This differs from work published previously that demon-
strated a recombinant form of SV40 Tag fails to induce
CD8+ T cells that secrete IL-2 as part of the observed late
phase tumor rejection in mice (Utermohlen et al., 2001).
These authors did demonstrate a role for both CD4+ and
CD8+ T cells in this in vivo tumor rejection, which is
similar to what was induced as the result of plasmid DNA
immunization described herein. Our laboratory has previ-
ously demonstrated a critical role for CD4+ T cells and
antibodies in tumor immunity induced by rSV40 Tag
immunization (Kennedy et al., 2003).
The data described here have shown that utilizing a CMV
promoter to express Tag within a plasmid allows for the
induction of an antibody response to SV40 Tag at greater
levels than that observed with pSV3-neo. Furthermore, mice
immunized with pCMV-Tag were completely protected from
both solid and experimental metastatic tumor challenges
while pSV3-neo mice demonstrated some protection in the
less stringent solid tumor challenge model. The strength of
the plasmid promoter clearly functions in the type of
protective immune response that will be induced. Our data
presently do not identify a lack of a particular CD4+ and
CD8+ Tcells response by the plasmid DNAs that account for
this observed difference in antibody responses and tumor
immunity. The potential exist that regulatory Tcells, CD4+ T
reg, or memory cells of the effector or central memory
phenotype may play some role and will be the subject of
further investigation (reviewed in Seder and Ahmed, 2003;
Wood and Sakaguchi, 2003). Clearly, even without knowl-
edge of the precise mechanisms, the CMV promoter confers
D.B. Lowe et al. / Virology 332 (2005) 28–3734that a high amount of SV40 Tag is delivered to induce both an
antibody response and complete systemic tumor protection
by plasmid vaccination. Therefore, pCMV-Tag represents a
potentially effective means to evaluate immunotherapy and
mechanisms of tumor immunity in mice with possible
application in future vaccination trials involving cancer
patients with SV40-Tag-expressing tumors (Rizzo et al.,
2001).Materials and methods
Plasmid DNA
The gene encoding for Tag of SV40 was cloned into the
bacterial plasmid pBR322, as previously described (Southern
and Berg, 1982). This DNA construct, designated pSV3-neo,
included the SV40 promoter and origin of replication, as well
as the neomycin resistance gene (Fig. 5). The plasmid, pSV2-
neo, that lacked the Tag gene was used as a control. The
plasmid pCMV-Tag was produced by excising the SV40 Tag
gene from pBRSV, a vector containing the complete SV40
genome, and introducing the Tag gene into the pcDNA3.1
plasmid under the control of the CMV promoter. Plasmid
DNAwas propagated in Escherichia coli and purified using a
plasmid prep kit (Qiagen, Valencia, CA) according to the
manufacturer’s instructions. Purified Plasmid DNA was
stored at 20 8C at a concentration of 1–3 mg/ml.
Cells and media
The BALB/c, mouse fibroblast cell line, designated NIH/
3T3, was used for plasmid transfection studies. Addition-
ally, the SV40-transformed BALB/c mouse fibroblast cell
line, designated mKSA (Kit et al., 1969), was used for
tumor cell challenge of mice. Both NIH/3T3 and mKSA
cells were cultured in Dulbecco’s modified eagle mediumFig. 5. Schematic representation of the plasmid DNA expressing the SV40 Tag tran
Tag plasmid on the pcDNA 3.1 backbone. AmpR and NeoR are the ampicillin an
replication. Tag denotes the large tumor antigen gene. BGH poly-A and SV40 p
SV40, respectively.(DMEM) with l-glutamine (HyClone, Logan, UT) and
supplemented with 0.1 mM nonessential amino acids, 100
U/ml penicillin, 100 Ag/ml streptomycin (Sigma, St. Louis,
MO), and 10% heat inactivated fetal bovine serum
(HyClone). Cells were incubated in a humidified, 5% CO2
atmosphere at 37 8C, whereby once confluent, cells were
passaged with trypsin/EDTA (Sigma).
In vitro transfection
Transient transfection was performed on the NIH/3T3
cell line using a modified lipofectamine method according
to the manufacturer’s specifications (Qiagen). Briefly, NIH/
3T3 cells were aliquoted to 2  105 cells per 6-well plate the
day prior to transfection. Two micrograms of plasmid DNA
was combined with both 100 Al DNA condensation buffer
and 3.2 Al enhancer solution and incubated at room
temperature for 2–5 min. Ten microliters of Effectene
Transfection Reagent was added, and the solution was
incubated further at room temperature for 5–10 min.
Following incubation, 600 Al of supplemented DMEM
growth medium was combined with DNA enhancer
solution. Cells were washed once with PBS, whereby
existing medium was exchanged for 1.6 ml supplemented
DMEM growth medium. Plasmid DNAwas added followed
by 48 h incubation of the cell culture.
RNA isolation and RT-PCR
RNA was isolated from cells using TRIzol Reagent
according to the manufacturer’s instructions (Invitrogen,
Carlsbad, CA). RNA was quantified by UV absorption
and stored at a concentration of 1 mg/ml. The integrity of
the RNA was further determined by electrophoresis using
1% agarose gels and ethidium bromide staining. After
reverse transcription of 2 Ag of DNA-free RNA using
oligo(dT) priming and Superscript First-Strand Synthesissgene. (A) pSV3-neo plasmid, which is on a pBR322 backbone. (B) pCMV-
d neomycin resistance genes, respectively. SV40 ori denotes the origin of
oly-A denote the poly-adenylation sites from bovine growth hormone and
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polymerase (Promega) in a total volume of 50 Al per
reaction. Primers for the detection of SV40 Tag were as
follows: (forward) 5V-CAAGCAACTCCAGCATC-3V and
(reverse) 5V-CCAGAAGAAGCAGAGGAAAC-3V. Pri-
mers for the detection of the housekeeping mouse gene,
GAPDH, were as follows: (forward) 5V-CCGGTGCTGA-
GTATGTGG-3V and (reverse) 5V-TCTGGGTGGCAGT-
GATGG-3V (Bright et al., 2002). PCR conditions were
an initial denaturation of 3 min at 94 8C, followed by 1
min denaturation at 94 8C, annealing for 1 min,
extension for 1 min at 72 8C for 30 cycles, and ending
with a 5-min extension at 72 8C. Annealing temperatures
were 61 8C for SV40 Tag primers and 60 8C for
GAPDH primers. Approximately, 5 Al aliquots of
amplification products were visualized on 1% agarose
gel with ethidium bromide staining. Band intensities of
amplification products obtained by electrophoresis were
further evaluated using the computer software program,
ImageQuant from Molecular Dynamics. In replicate
experiments, real-time PCR was performed using the
SV40 Tag primers to insure that equivalent amounts of
plasmid were examined and to normalize for transfection
efficiencies.
Western blot
Western blot analysis was performed on whole cell
lysates in order to confirm SV40 Tag expression in
transiently transfected NIH/3T3 cells. Briefly, cells in 6-
well plates were washed three times with PBS and lysed
with 200 Al RIPA lysis buffer containing 150 mM NaCl, 1%
NP-40, 0.5% DOC, 0.1% SDS, and 50 mM Tris–HCL (pH
8.0). Following supernatant clarification by high-speed
centrifugation, the protein concentrations in the lysates
were determined based on a BSA standard using a Bradford
assay and equivalent amounts of protein were added. These
samples were resolved on 10% SDS-PAGE and then
electrotransferred to a nitrocellulose membrane. The pres-
ence of SV40 Tag in cell lysates was detected using a
monoclonal antibody to SV40 Tag conjugated to horse-
radish peroxidase (HRP). Blots were developed using a
peroxidase sensitive substrate, Supersignal West Pico
Chemiluminescent (Pierce, Rockford, IL). Blots were
further evaluated using the computer software program
ImageQuant from Molecular Dynamics.
Immunization and tumor cell challenge
Six- to eight-week-old female BALB/c mice (Charles
River Laboratories, Wilmington, MA) were maintained
under standard conditions. Treatment and care of the
animals were in accordance with institutional guidelines
and the Animal Welfare Assurance Act. Groups of 10 mice
were immunized using 100 Ag of plasmid DNA in saline at
2-week intervals, a total of four times, via injection into thequadriceps muscles of both hind legs. Serum was collected
prior to injection and 14 days following each injection and
used to determine antibody responses to SV40 Tag. Control
groups of mice received one injection containing 2 Ag of
alum precipitate of rSV40 Tag followed by three 1 Ag
injections every 14 days.
Approximately 14 days after final immunization, mice
were challenged either via intraperitoneal injection with 1 
107 or intravenous injection with 5  105 mKSA in saline.
Three mice from each intravenous challenge group were
euthanized 18 days posttumor cell challenge, and the
number of tumor cell foci in the lungs was determined.
The remaining mice from each group were used to
determine survival time.
ELISA
Antibodies to SV40 Tag and antibody endpoint titer
determinations of mouse sera were carried out using indirect
ELISA as previously described (Bright et al., 1993; Shearer
et al., 1990, 1993). Briefly, 50 Al of rSV40 Tag at a final
concentration of 200 ng in borate-buffered saline (BBS) was
coated onto 96-well microtiter plates and incubated at 37 8C
for 1 h. Nonspecific binding sites were blocked by the
addition of 200 Al blocking solution and incubated at 37 8C
for 30 min. Various dilutions of mouse sera was added in
triplicate and incubated for 1 h at 37 8C. Anti-SV40 Tag
reactivity was detected using a goat anti-mouse IgG Fc-
specific reagent conjugated with HRP for 30 min at 37 8C.
Microtiter wells were developed with 100 Al of peroxidase
substrate 2,2V-azino-di(3-ethylbenzthiazoline sulfonic acid)
(ABTS) containing 0.01% H2O2. Enzyme substrate reac-
tions were terminated by the addition of 100 Al of 5% (w/v)
SDS. An optical density (OD) of 410 nm, determined to be
approximately three times the OD values obtained for 1:20
dilutions of the preimmune sera, was established as a cutoff
for positive reactivity and antibody endpoint titer determi-
nations (Wolf et al., 1992). Immune serum was examined
using serial dilutions, beginning with a dilution of 1:50, and
a final dilution that resulted in an OD above the cutoff was
the endpoint titer.
FACS analysis
Groups of three mice were immunized and challenged as
described. At 7 days postchallenge the mice were euthan-
ized, spleens removed and homogenized in PBS. The bulk
cell suspension was loaded onto Histopaque-1077 gradients
and centrifuged for 30 min at 400  g. The opaque
lymphocyte-containing layer was harvested and washed
two times with PBS. The final cell pellet was resuspended
in 5 ml RPMI supplemented with PMA (50 ng/ml),
ionomycin (1 AM), and brefeldin A (1 Ag/ml) and
stimulated for 5 h at 37 8C prior to staining. All staining
reagents were purchased from BD Biosciences Pharmingen,
San Diego, CA (http://www.bdbioscience.com). Approx-
D.B. Lowe et al. / Virology 332 (2005) 28–3736imately 1  106 cells per test were aliquoted into 1.5 ml
microcentrifuge tubes and pelleted at 200  g for 5 min.
The pellets were resuspended in 100 Al of blocking buffer
consisting of PBS, 1% BSA, 0.5% sodium azide, and 100
ng of purified anti-mouse CD16/CD32, Fc III/II Receptor
(BD 556678), and incubated for 20 min at room temper-
ature in the dark. After the blocking period, cell surface
molecules were stained by addition of 100 ng of either Cy-
chrome rat anti-mouse CD4 (BD 553050) or Cy-chrome rat
anti-mouse CD8 (BD 553050) and reincubated for another
20 min. After surface staining, the cells were pelleted and
fixed by resuspension in 100 Al of cytofix/cytoperm buffer
(BD 554722) and incubated for 20 min. After fixation, the
cells were pelleted and permeabilized by resuspended in
100 Al of perm/wash buffer (BD 554723) that contained
100 ng of anti-cytokine antibodies PE-rat anti-mouse IL-2
(BD 554428), PE-rat anti-mouse IL-4 (BD 554435), PE-rat
anti-mouse IL-10 (BD 554467), and PE-rat anti-mouse
IFN-g (BD 554412) and incubated for 20 min. After
intracellular cytokine staining, the cells were pelleted and
resuspended in 1 ml of FACS flow sheathe fluid. Samples
were analyzed on a Becton Dickson FACSVantage SE
instrument using CELLQuest software. Routinely, 1  105
cells were analyzed for staining of the ex vivo splenic
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